PMID- 20109611
OWN - NLM
STAT- MEDLINE
DCOM- 20100401
LR  - 20211020
IS  - 1532-8686 (Electronic)
IS  - 0037-1963 (Print)
IS  - 0037-1963 (Linking)
VI  - 47
IP  - 1
DP  - 2010 Jan
TI  - Transplant outcomes in acute leukemia. I.
PG  - 46-50
LID - 10.1053/j.seminhematol.2009.10.007 [doi]
AB  - Umbilical cord blood (UCB) has gradually emerged over the last decade as an 
      alternative source of hematopoietic cells for transplantation in children and 
      adults with high-risk or advanced hematologic malignancies who do not have a 
      suitably matched related or unrelated adult donor. This increase in use of UCB is 
      due to favorable results in children, growing availability of UCB units with 
      large cell doses, less stringent donor-recipient HLA matching, and rapid 
      identification and acquisition of the unit. In children with acute leukemia, the 
      data support similar leukemia-free survival after transplantation of human 
      leukocyte antigen (HLA)-matched and one or two HLA-mismatched UCB and HLA-matched 
      unrelated donor bone marrow. In adults with acute leukemia, some reports suggest 
      a survival advantage after transplantation of matched unrelated bone marrow 
      compared to UCB, while others report similar leukemia-free survival. Work is in 
      progress to improve hematopoietic recovery and lower early transplant-related 
      deaths, the two major limitations to a successful outcome after UCB transplant. 
      The importance of HLA-matching and cell dose on outcomes after UCB 
      transplantation support the need for an even greater investment in public cord 
      blood banks. Simultaneously searching of accredited cord blood banks and bone 
      marrow donor registries for patients without an HLA-matched sibling thought to 
      benefit from hematopoietic stem cell transplantation (HSCT) is encouraged.
CI  - (c) 2010 Elsevier Inc. All rights reserved.
FAU - Eapen, Mary
AU  - Eapen M
AD  - Statistical Center, Center for International Blood and Marrow Transplant 
      Research, Medical College of Wisconsin, Milwaukee, WI 53226, USA. meapen@mcw.edu
FAU - Wagner, John E
AU  - Wagner JE
LA  - eng
GR  - U24 CA076518/CA/NCI NIH HHS/United States
GR  - U24 CA076518-12/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Hematol
JT  - Seminars in hematology
JID - 0404514
SB  - IM
MH  - Adult
MH  - Blood Donors/supply & distribution
MH  - Child
MH  - *Cord Blood Stem Cell Transplantation/adverse effects/mortality
MH  - Graft vs Host Disease/etiology
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects/mortality
MH  - Histocompatibility Testing
MH  - Humans
MH  - Leukemia/mortality/*surgery
MH  - Patient Selection
MH  - Recurrence
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC2814074
MID - NIHMS156329
EDAT- 2010/01/30 06:00
MHDA- 2010/04/02 06:00
PMCR- 2011/01/01
CRDT- 2010/01/30 06:00
PHST- 2010/01/30 06:00 [entrez]
PHST- 2010/01/30 06:00 [pubmed]
PHST- 2010/04/02 06:00 [medline]
PHST- 2011/01/01 00:00 [pmc-release]
AID - S0037-1963(09)00138-3 [pii]
AID - 10.1053/j.seminhematol.2009.10.007 [doi]
PST - ppublish
SO  - Semin Hematol. 2010 Jan;47(1):46-50. doi: 10.1053/j.seminhematol.2009.10.007.